Hoffmann-La Roche Inc.

Merck Sharp + Dohme Corp.

F. Hoffmann-La Roche Ag

European Molecular Biology Laboratory

Savira Pharmaceuticals Gmbh

Chugai Pharmaceutical Co.

Merck Sharp & Dohme LLC

Chugai Seiyaku Kabushiki Kaisha

Sung-Sau So

Fariborz Firooznia

Tai-An Lin

Francisco Javier Lopez-Tapia

Eric Mertz

Amjad Ali

Paul Gillespie

Achyutharao Sidduri

Romyr Dominique

Li Chen

Yimin Qian

Hongying Yun

Jefferson Wright Tilley

Helmut Heinrich Buschmann

Mark Smith

Yun He

Scott D Edmondson

Kshitij Chhabilbhai Thakkar

Stephen Cusack

Norbert Handler

Oliver Szolar

Andrea Wolkerstorfer

Ying-Duo Gao

Rongze Kuang

Anthony K Ogawa

Weiguo Liu

Ronald Charles Hawley

Kin-Chun Thomas Luk

John S Debenham

Nancy-Ellen Haynes

Alan W Hruza

Wanying Sun

Norman Kong

Hongju Li

Qi Qiao

Pamela Loreen Rossman

Zhenshan Zhang

Yan Lou

Shawn David Erickson

Peter Michael Wovkulich

Denis John Kertesz

Zhuyan Guo

Sherrie Lynn Pietranico-Cole

Christine E Brotherton-Pleiss

Jacqueline D Hicks

Heping Wu

Nathan Robert Scott

Jenny Tan

Matthew Lombardo

Brian Alexander McKittrick

Zhicai Wu

Zhuming Zhang

Ramakanth Sarabu

Robert Alan Goodnow, Jr

Allen John Lovey

Peter Orth

Santhosh Francis Neelamkavil

Linda Brockunier

Kyungjin Kim

Dexi Yang

Brent Whitehead

Jerry Andrew Taylor

Zhi Chen

Jiafang He

John Lawson Roberts

Hong Dong Chu

Lin Yi

Wenlang Fu

Peter Nizner

Daniel A Tatosian

Joseph P Lyssikatos

Jared N Cumming

Yi Heng Chen

Anandan Palani

Anthony A Estrada

Huifen Chen

Dong Xiao

Hongjun Zhang

Robert R Wilkening

Javier De Vicente Fidalgo

David L Sloman

Lichun Feng

Stefan Scheiblich

Timothy D Owens

Cheng Zhu

Robert Francis Kester

Derun Li

Binh Vu

Jin-Jun Liu

Giacomo Pizzolato

Bruno Giethlen

Roland Joseph Billedeau

Abdelghani Achab

Rama K Kondru

Qingjie Ding

Shaoqing Chen

Wendy Lea Corbett

Christian Fischer

Charles A Lesburg

The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more compounds of Formula I compounds, and methods for using the compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.

Factor XIa inhibitors

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XI activation inhibitors.

Factor XI activation inhibitors

Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as arginase inhibitors and can be useful in preventing, treating or acting as a remedial agent for arginase-related diseases.

Arginase inhibitors and methods of use

This application discloses compounds according to generic Formula (I): wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are useful for the treatment of oncological, auto-immune, and inflammatory diseases caused by aberrant B-cell activation. Also disclosed are compositions containing compounds of Formula (I) and at least one carrier, diluent or excipient. 

Inhibitors of bruton's tyrosine kinase

The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIIa inhibitors. 

Factor XIIa inhibitors

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIIa inhibitors. 

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein. 

The present invention provides a compound of Formula (I); and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein. 

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoaguability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein. 

The present invention provides a compound of Formula (I) (Formula (I)) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein. 

This application discloses compounds according to generic Formula (I): wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are useful for the treatment of oncological, auto-immune, and inflammatory diseases caused by aberrant B-cell activation. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient. 

Growing community of inventors

Verona, NJ, United States of America

Sung-Sau So